Baxter International, Inc. Initiates Phase III Adult Stem Cell Clinical Trial for Chronic Cardiac Condition

Published: Feb 28, 2012

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) announced today that it has initiated a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous (an individual’s own) CD34+ stem cells to increase exercise capacity in patients with chronic myocardial ischemia (CMI).

Back to news